
Sign up to save your podcasts
Or
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
4.5
187187 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
1,858 Listeners
1,161 Listeners
379 Listeners
1,462 Listeners
1,109 Listeners
106 Listeners
3,992 Listeners
1,392 Listeners
749 Listeners
106 Listeners
163 Listeners
783 Listeners
648 Listeners
220 Listeners
70 Listeners
155 Listeners
81 Listeners